Investors

27 August 2024

Biochip experiments begin to develop kidney disease testing

→

16 August 2024

New Integrated biochip gFET to bolster functionality

→

26 July 2024

Quarterly Activity Report & Appendix 4C

→

23 July 2024

New Biochip gFET test procedure and process developed

→

18 July 2024

Quantum technology project update

→

15 July 2024

Management restructure

→

12 July 2024

Departure of CEO

→

28 June 2024

Notification of cessation of securities - AXE

→

17 June 2024

Archer Biochip gFET design fabricated on a six-inch wafer

→

09 May 2024

Notification of cessation of securities - AXE

→

29 April 2024

Quarterly Activity Report & Appendix 4C

→

09 April 2024

Change in substantial holding from AXE

→

05 April 2024

Sharecafe Investor Presentation

→

02 April 2024

Change of Director's Interest Notice

→

25 March 2024

Archer and EPFL develop a single chip pulsed ESR microsystem

→

11 March 2024

Archer miniaturises Biochip gFET chip design

→

16 February 2024

Appendix 4D and Half Year Financial Report

→

24 January 2024

Quarterly Activity Report & Appendix 4C

→

16 January 2024

Notification of cessation of securities - AXE

→